BioCryst to close Birmingham lab and shift to external R&D model
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- Matador Resources to acquire Paloma Permian for $1.275B
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
June 29, 2026 7:00 AM EDTAdvances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth
Completes enrollment in Phase 3 ALPHA-ORBIT for navenibart, largest pivotal HAE study to date
Resolves previously disclosed manufacturing delay of ORLADEYO® (berotralstat) oral pellets; product to be available in early August
Improves 2026 non-GAAP operating expense guidance from $450-$470 million to $420-$440 million and reaffirms revenue guidance
RESEARCH TRIANGLE PARK, N.C., June 29, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX)... More
